<DOC>
	<DOCNO>NCT00513318</DOCNO>
	<brief_summary>This pilot study design evaluate safety feasibility perform umbilical cord blood transplant old adult young infirm patient high-risk hematopoeitic malignancy . A novel reduced-intensity preparative regimen umbilical cord blood transplantation use . One maximum three cord blood unit , depend cell count , administer facilitate engraftment . Ten patient enrol expect accrual rate 3-4 patient per year goal complete accrual within 2-3 year .</brief_summary>
	<brief_title>Pilot Study Reduced-Intensity Umbilical Cord Blood Transplantation Adult Patients Wtih Advanced Hematopoietic Malignancies</brief_title>
	<detailed_description>Primary Objective : - To assess feasibility perform umbilical cord blood transplant old adult young infirm patient use reduced-intensity preparative regimen . Feasibility procedure define engraftment rate &gt; 80 % Day 180 post-transplantation transplant relate mortality ( TRM ) &lt; 50 % Day 100 . A TRM &gt; 50 % consider unacceptable . Secondary objective : - To describe time neutrophil platelet recovery follow mini-UCB transplantation . - To assess lineage-specific chimerism follow transplantation describe contribution individual CB unit post-transplantation hematopoeisis . - To describe disease-specific , event-free overall survival rate 180 360 day . - To describe incidence , severity , time acute chronic GVHD follow reduced-intensity UCB transplantation . - To evaluate T-cell , B-cell , NK cell recovery follow reduced-intensity UCB transplantation .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<criteria>Age 5570 year , &lt; 55 year deem ineligible conventional high dose chemotherapy UCSF SCT Committee protocol eligibility requirement myeloablative therapy . Reasons ineligibility myeloablative therapy include : Poor cardiac function ( i.e . LVEF &lt; 40 % ) Poor pulmonary function ( i.e . DLCO &lt; 50 % ) Hepatic dysfunction Prior myeloablative therapy Availability donor cord blood ( one three unit ) match &gt; equal 4 6 HLA antigen ( A , B , DR ) . HLA class I antigens determined serologic method , Class II antigen determine highresolution DNA typing . Typing confirm UCSF Immunogenetics Department . The target UCB TNC dose &gt; equal 3.5 x 10 ( 7 ) TNC/kg recipient weight , however absolute minimum TNC requirement &gt; 2.5 x 10 ( 7 ) TNC per kilogram ) base cell count prior cryopreservation . Cord blood unit obtain available international bank . HLA identical 1 antigen mismatch related donor potential HLAmatched unrelated donor ( MUD ) must NOT readily available Disease type include : Acute myeloid leukemia expect curable chemotherapy . This include patient highrisk cytogenetics ( 7 , 7q , 5 , 5q , ( 6 , 9 ) , ( 9 , 11 ) , complex ( &gt; equal 3 abnormality ) , Ph ( + ) , evolution prior myelodysplasia AML secondary prior chemotherapy , failure achieve remission , second , subsequent remission refractory relapse . Marrow blast must &lt; equal 10 % . This may achieve use standard chemotherapy treatment . Myelodysplasia highrisk feature . This include patient IPSS category INT2 HIrisk MDS CMML . Marrow blast must &lt; equal 20 % . If require , chemotherapy may give achieve target level blast . Patients expected disease control rapidly progressive disease regardless blast count ( must &lt; equal 20 % ) . Acute lymphoblastic leukemia expect cured chemotherapy . This include patient highrisk cytogenetics ( Ph+ , ( 4,11 ) , 11q23 abnormality , monosomy 7 ) , patient require one induction course achieve remission , well patient fail enter remission second subsequent remission . Marrow blast must &lt; equal 10 % . If require , chemotherapy may give achieve target level blast . Chronic myelogenous leukemia chronic phase fail imatinib mesylate therapy ( either progressive disease failure achieve major cytogenetic response 1 year follow initiation therapy ) , accelerate phase fail achieve complete cytogenetic remission 1 year follow initiation therapy , accelerate phase fail achieve cytogenetic response 6 month therapy , accelerate phase progressive disease demonstrate worsen cytogenetic response two consecutive analysis separate 4 week CML blast crisis . Patients blast phase CML must &lt; 10 % blast bone marrow . Multiple myeloma stage IIII relapse follow autologous transplant , disease refractory least two prior conventional ; myeloma therapy chromosome 13 abnormality . Patients chromosome 13 abnormality eligible either diagnosis initial progression . Lymphomas include diffuse follicular large cell lymphoma , mantle cell lymphoma , peripheral Tcell lymphoma , TNK cell lymphoma , Hodgkin 's disease fail respond primary therapy , progress , recur prior therapy . Patients relapse follow autologous transplant eligible . Lowgrade NHL Chronic Lymphocytic Leukemia relapse refractory disease follow , least , two chemotherapybased treatment regimen ; relapse follow autologous transplantation . Patients must ECOG PS &lt; equal 2 . Laboratory requirement : Creatinine &lt; 2.0mg/dL creatinine clearance &gt; 40/m/min ( calculate base 24hour urine collection ) Bilirubin &lt; 2.0mg/dL , AST/alkphos &lt; 3x upper limit normal Patients hepatitis C active hepatitis B ( hepatitis B DNA detectable ) eligible liver biopsy perform grade &lt; equal 2 fibrosis and/or inflammation . Patients history HBV infection test HBeAg , antiHBe HBV DNA ( quantitative ) . Patients active HBV viral replication receive antiviral therapy . Cardiac ejection fraction &gt; 30 % , DLCO &gt; equal 40 % . Negative pregnancy test ( female reproductive age ) . Signed informed consent Active infection require ongoing antibiotic treatment HIV infection Poor performance status ( ECOG &gt; 2 ) Opinion BMT Committee autologous SCT conventional therapy would preferable form treatment Organ function requirement Pregnancy , breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Umbilical cord blood transplantation</keyword>
	<keyword>hematopoietic malignancy</keyword>
</DOC>